PetCure Oncology says it has treated 10,000 patients

PetCure Oncology says it has now treated 10,000 patients, a milestone the company is framing as evidence that advanced radiation therapy has moved beyond a niche academic offering and into broader specialty practice. In its January 7, 2026 announcement, the Thrive Pet Healthcare-affiliated network said its growth over the past decade has centered on expanding access to stereotactic radiation therapy, which can condense treatment from the historical 15 to 20 fractions to as few as one to three sessions for selected cases. PetCure previously announced an 8,000-patient milestone in April 2024, and company materials now say more than 10,000 pet families have used its services. Industry listings and company reports indicate the network operates in seven U.S. markets, plus one standalone comprehensive cancer center, with additional technology expansion underway. The company has also been signaling that its next chapter may extend beyond standard fixed-site radiation programs, including interest in compact, self-contained systems that could expand access by avoiding the need for a dedicated radiation vault and, in some cases, allowing CT, treatment planning, and treatment delivery under a single anesthetic event. (petcureoncology.com)

Why it matters: For veterinary professionals, the bigger story isn't the round number. It's what the milestone suggests about referral behavior, case volume, and client willingness to pursue radiation when logistics are manageable. PetCure and other oncology groups have argued for years that access, not just clinical interest, has limited use of radiation therapy in companion animals. In company commentary, chief medical officer Neal Mauldin has tied the rise of stereotactic protocols directly to the realities of veterinary access, noting that families may live 8 to 10 hours from a radiation facility and are more likely to pursue care when treatment can be completed in days rather than weeks. The Veterinary Cancer Society’s facility listings show radiation remains concentrated in a relatively small number of centers, while PetCure has built a distributed model around referral partnerships, board-certified oncology support, and shorter-course treatment options. For general practitioners and specialists, that means radiation is increasingly a practical referral discussion for some tumors, especially when fewer anesthetic events, shorter treatment timelines, and geographic proximity may improve follow-through for pet parents. PetCure is also publicly pointing to adjacent areas that could broaden how radiation is used in practice, including planned research combining radiation with immunotherapy in cats with oral squamous cell carcinoma, low-dose radiation for chronic inflammatory conditions such as feline cystitis, stomatitis, and osteoarthritis, and low dose-rate radiation therapy as a potential add-on in canine B-cell lymphoma protocols. (petcureoncology.com)

What to watch: Watch whether PetCure’s next phase is defined less by patient-count milestones and more by new site openings, technology rollouts like the Sirius platform, and published outcomes data that help practices decide which cases benefit most from referral. Also worth watching: whether the company’s stated interest in mobile or compact radiation platforms, radiation-immunotherapy combinations, and nontraditional indications for low-dose radiation translates into peer-reviewed evidence and broader clinical adoption. (empyreanmed.com)